Hemophilia A

New England CEPAC
March 29, 2018 10am-4pm ET

Boston Marriott Cambridge
50 Broadway
Cambridge, MA, 02142

The New England CEPAC will convene to review the comparative clinical effectiveness and value of emicizumab for treatment of hemophilia A.

Key Dates

Associated Materials

08/11/2017

08/11/2017 – 09/06/2017

09/11/2017

09/11/2017 – 09/29/2017

10/10/2017

11/21/2017

11/21/2017

01/26/2018

01/26/2018

Open to public comment until February 23, 2018 at 5pm ET. For more information on submitting a public comment, visit our engagement page.